Mobile

MK-3682 + Ruzasvir for 12 weeks in Subjects with HCV GT1-6 Infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003227-37

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

-To evaluate the efficacy of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg) as assessed by the proportion of subjects achieving sustained virologic response (SVR) at 12 weeks post-treatment (SVR12) (defined as HCV ribonucleic acid [RNA] <lower limit of quantification [LLOQ] 12 weeks after the end of all study therapy). -To evaluate the safety and tolerability of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg).

Critère d'inclusion

  • Treatment of chronic hepatitis C virus (HCV) infection

Liens